Bioprosthetic Valve Fracturing in Valve‐in‐Valve TAVI: Clinical and Echocardiographic Outcomes in Failing Perimount Aortic Bioprostheses—A Multicenter Registry
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31686 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Hendrik Ruge und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Institute Insure, German Heart Center Munich, School of Medicine & Health, Technical University of Munich, Muni…. Hauptthemen laut MEDLINE: Bioprosthesis, Heart Valve Prosthesis, Transcatheter Aortic Valve Replacement, Aortic Valve. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
Data comparing clinical and hemodynamic outcomes of bioprosthetic valve fracturing (BVF) and “standard”‐postdilatation during valve‐in‐valve transcatheter heart valve implantation (ViV‐TAVI) are lacking. The authors aimed to analyze hemodynamic and clinical outcomes of BVF compared to “standard”‐postdilatation during ViV‐TAVI.
Methods
The REDUCE registry included patients who underwent ViV‐TAVI within a Perimount surgical aortic valve bioprosthesis (Edwards Lifesciences, USA). Procedures were categorized to no postdilatation, “standard”‐postdilatation and BVF. Hemodynamic and clinical outcomes at 30 days were collected and compared. A linear regression model was built to predict mean aortic gradient after ViV‐TAVI.
Results
A total of 240 patients from six European sites were included. Median age was 78 years [IQR 70; 83], logistic EuroSCORE calculated 20.0%[IQR 12.2; 33.1] and 159 patients (66%) were male. One hundred fourty‐four Perimount valves (60%) had a true internal diameter (ID) ≤ 21 mm. Self‐expanding valves (SEV) and ballon‐expandable valves (BEV) were used in 60% and 40% of cases, respectively. One hundred sixteen procedures (48%) were executed without postdilatation, in 88 procedures (37%) “standard”‐postdilatation and in 36 procedures (15%) BVF was used. 30‐day survival was 93.3%. VARC‐3 device success at 30 days was 71%. A multivariable regression analysis of the mean aortic gradient after ViV‐TAVI showed a significant association with surgical valve size (−0.84 mmHg, p = 0.001; per 1 mm surgical valve size increase), execution of postdilatation (−3.25 mmHg, p = 0.007) and type of transcatheter heart valve (SEV: −7.31 mmHg, p < 0.001).
Conclusions
When performing ViV‐TAVI within a Perimount surgical aortic bioprosthesis with a true ID ≤ 21 mm, the hemodynamic valve performance is most optimal when implanting a SEV‐TAV and when postdilating the TAV‐in‐SAV complex. BVF did not result in superior hemodynamics compared to “standard”‐postdilatation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Institute Insure, German Heart Center Munich, School of Medicine & Health, Technical University of Munich, Munich, Germany.
- German Center for Cardiovascular Research (DZHK), partner side Hamburg/Kiel/Lübeck, Kiel, Germany.
- Department of Internal Medicine III, Cardiology and Critical Care, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
- Med. Clinic I, Cardiology & Angiology University of Giessen und Marburg GmbH, Giessen, Germany.
- Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany.
- The Heart Center, Rigshospitalet, Copenhagen, Denmark.
ORCID-Profile: Hendrik Ruge, Won-Keun Kim, Andreas Schäfer, Chiara Fraccaro
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Ruge, H., Burri, M., Schreyer, J., Georgescu, T. C., Frank, D., Kim, W. K., de Backer, O., Beyer, M., Schäfer, A., Fraccaro, C., Tarantini, G., Xhepa, E., Joner, M., Krane, M., & Covarrubias, H. A. A. (2025). Bioprosthetic Valve Fracturing in Valve‐in‐Valve TAVI: Clinical and Echocardiographic Outcomes in Failing Perimount Aortic Bioprostheses—A Multicenter Registry. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31686
Vancouver
Ruge H, Burri M, Schreyer J, Georgescu TC, Frank D, Kim WK, et al. Bioprosthetic Valve Fracturing in Valve‐in‐Valve TAVI: Clinical and Echocardiographic Outcomes in Failing Perimount Aortic Bioprostheses—A Multicenter Registry. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31686
BibTeX
@article{Ruge2025,
author = {Ruge, Hendrik and Burri, Melchior and Schreyer, Julia and Georgescu, Teodora-Cristiana and Frank, Derk and Kim, Won-Keun and de Backer, Ole and Beyer, Martin and Schäfer, Andreas and Fraccaro, Chiara and Tarantini, Giuseppe and Xhepa, Erion and Joner, Michael and Krane, Markus and Covarrubias, Héctor Alfonso Alvarez},
title = {Bioprosthetic Valve Fracturing in Valve‐in‐Valve TAVI: Clinical and Echocardiographic Outcomes in Failing Perimount Aortic Bioprostheses—A Multicenter Registry},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31686}
}
EUVIMED